We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Immunocore Hits Enrollment Target in Kimmtrak Label Expansion Study
Read MoreHide Full Article
Key Takeaways
IMCR enrolled 540 patients in the TEBE-AM study evaluating Kimmtrak in previously treated advanced melanoma.
The study tests Kimmtrak alone and with Keytruda versus investigator's choice after prior therapy.
IMCR expects top-line overall survival data as early as year-end 2026, a potential near-term catalyst.
Immunocore (IMCR - Free Report) announced that it has achieved target enrollment of 540 patients in the phase III TEBE-AM study, which is evaluating its sole marketed drug, Kimmtrak (tebentafusp), in patients with second-line or later advanced melanoma.
The randomized, registrational phase III TEBE-AM study is evaluating Kimmtrak as a monotherapy and in combination with Merck’s (MRK - Free Report) blockbuster PD-L1 inhibitor, Keytruda (pembrolizumab) versus investigator’s choice (control arm) in HLA-A*02:01-positive patients with advanced melanoma whose disease progressed after prior therapy.
Overall survival is the primary endpoint of the TEBE-AM study.
Merck’s biggest revenue driver, Keytruda, is approved for several cancer indications. MRK recorded $16.40 billion in Keytruda sales in the first half of 2026, up 4.2% year over year.
Immunocore expects to report top-line overall survival data from the TEBE-AM study as early as the end of 2026. If the study data are successful, they could provide meaningful visibility into Kimmtrak's potential in the previously treated advanced melanoma setting.
Per management, Kimmtrak could address a significant unmet need among up to 4,000 HLA-A*02:01-positive patients with previously treated advanced melanoma in the post-PD1 setting.
IMCR’s Price Performance
Year to date, shares of Immunocore have lost 6.4% against the industry’s increase of 5.8%.
Image Source: Zacks Investment Research
IMCR Thrives on Kimmtrak Sales Uptake
Kimmtrak is presently approved for treating patients with unresectable or metastatic uveal melanoma (mUM). Currently, Immunocore’s top line solely comprises worldwide net product sales of Kimmtrak. The drug has been witnessing strong demand.
Kimmtrak continues to generate solid sales growth globally. In the first half of 2026, Kimmtrak sales rose 16% year over year to $222.6 million. The strong commercial performance of Kimmtrak is expected to continue through the rest of 2026.
Since its approval and launch, Kimmtrak has established itself as the standard of care for eligible patients with metastatic uveal melanoma in most markets where it has been launched.
Kimmtrak continues to witness healthy adoption, supported by increasing physician awareness, broader reimbursement coverage and geographic expansion.
IMCR’s Zacks Rank & Stocks to Consider
Immunocore currently carries a Zacks Rank #3 (Hold).
Over the past 60 days, estimates for Anika Therapeutics’ 2026 bottom line have moved from a loss of 12 cents per share to earnings of $1.05 per share. Earnings estimates for 2027 have increased from 16 cents to 95 cents during the same time. ANIK’s shares have surged 120.5% year to date.
Anika Therapeutics’ earnings beat estimates in each of the trailing three quarters, with the average surprise being 950.00%.
Over the past 60 days, estimates for Precigen’s 2026 bottom line have moved from a loss of 2 cents per share to earnings of 25 cents. Earnings estimates for 2027 have increased from 25 cents to 86 cents during the same time. PGEN’s shares have rallied 63.9% year to date.
Precigen’s earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion, with the average surprise being 108.96%.
View the Zacks #1 Rank List
Image: Bigstock
Immunocore Hits Enrollment Target in Kimmtrak Label Expansion Study
Key Takeaways
Immunocore (IMCR - Free Report) announced that it has achieved target enrollment of 540 patients in the phase III TEBE-AM study, which is evaluating its sole marketed drug, Kimmtrak (tebentafusp), in patients with second-line or later advanced melanoma.
The randomized, registrational phase III TEBE-AM study is evaluating Kimmtrak as a monotherapy and in combination with Merck’s (MRK - Free Report) blockbuster PD-L1 inhibitor, Keytruda (pembrolizumab) versus investigator’s choice (control arm) in HLA-A*02:01-positive patients with advanced melanoma whose disease progressed after prior therapy.
Overall survival is the primary endpoint of the TEBE-AM study.
Merck’s biggest revenue driver, Keytruda, is approved for several cancer indications. MRK recorded $16.40 billion in Keytruda sales in the first half of 2026, up 4.2% year over year.
Immunocore expects to report top-line overall survival data from the TEBE-AM study as early as the end of 2026. If the study data are successful, they could provide meaningful visibility into Kimmtrak's potential in the previously treated advanced melanoma setting.
Per management, Kimmtrak could address a significant unmet need among up to 4,000 HLA-A*02:01-positive patients with previously treated advanced melanoma in the post-PD1 setting.
IMCR’s Price Performance
Year to date, shares of Immunocore have lost 6.4% against the industry’s increase of 5.8%.
Image Source: Zacks Investment Research
IMCR Thrives on Kimmtrak Sales Uptake
Kimmtrak is presently approved for treating patients with unresectable or metastatic uveal melanoma (mUM). Currently, Immunocore’s top line solely comprises worldwide net product sales of Kimmtrak. The drug has been witnessing strong demand.
Kimmtrak continues to generate solid sales growth globally. In the first half of 2026, Kimmtrak sales rose 16% year over year to $222.6 million. The strong commercial performance of Kimmtrak is expected to continue through the rest of 2026.
Since its approval and launch, Kimmtrak has established itself as the standard of care for eligible patients with metastatic uveal melanoma in most markets where it has been launched.
Kimmtrak continues to witness healthy adoption, supported by increasing physician awareness, broader reimbursement coverage and geographic expansion.
IMCR’s Zacks Rank & Stocks to Consider
Immunocore currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Anika Therapeutics (ANIK - Free Report) and Precigen (PGEN - Free Report) , both sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Anika Therapeutics’ 2026 bottom line have moved from a loss of 12 cents per share to earnings of $1.05 per share. Earnings estimates for 2027 have increased from 16 cents to 95 cents during the same time. ANIK’s shares have surged 120.5% year to date.
Anika Therapeutics’ earnings beat estimates in each of the trailing three quarters, with the average surprise being 950.00%.
Over the past 60 days, estimates for Precigen’s 2026 bottom line have moved from a loss of 2 cents per share to earnings of 25 cents. Earnings estimates for 2027 have increased from 25 cents to 86 cents during the same time. PGEN’s shares have rallied 63.9% year to date.
Precigen’s earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion, with the average surprise being 108.96%.